Why These 15 Stocks Are Skyrocketing in 2025

Page 8 of 14

7. Blueprint Medical (NASDAQ:BPMC)

Number of Hedge Fund Holders In Q3 2024: 37

Blueprint Medical (NASDAQ:BPMC) is a biopharma company that makes medicine for allergies, inflammation, and a number of cancers.

The lead product here is AYVAKIT (avapritinib). It is approved for several forms of systemic mastocytosis, and the company’s pipeline includes an oral KIT inhibitor called BLU-808, which is in development for allergic and inflammatory diseases.

BPMC stock surged in 2025 due to it updating its long-term outlook and announcing new data. It reaffirmed a large revenue opportunity for its systemic mastocytosis franchise. In January 2025, it said that AYVAKIT’s launch showed momentum and that new epidemiology data showed systemic mastocytosis was more common than previously thought. Not only that, Phase 1 results for BLU-808 came in positive.

Recent filings also show revenue gains have been solid, and losses have narrowed a lot more than previously expected. Management also guided for $475 million to $480 million in full-year 2024 AYVAKIT revenue. That means over 130% year-over-year growth. It forecasts AYVAKIT alone could reach $2 billion in annual revenue by 2030. Revenue from the overall systemic mastocytosis franchise could approach some $4 billion at its peak.

The consensus analyst price target on BPMC stock is at $126, implying 8.9% upside.

BPMC stock is up 32.57% year-to-date.

Page 8 of 14